

United States Recurrent Glioblastoma Multiforme Treatment Market Report 2018

https://marketpublishers.com/r/U31118D96BFEN.html

Date: January 2018 Pages: 105 Price: US\$ 3,800.00 (Single User License) ID: U31118D96BFEN

Abstracts

In this report, the United States Recurrent Glioblastoma Multiforme Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Recurrent Glioblastoma Multiforme Treatment in these regions, from 2013 to 2025 (forecast).

United States Recurrent Glioblastoma Multiforme Treatment market competition by top manufacturers/players, with Recurrent Glioblastoma Multiforme Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player;



the top players including

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Cavion LLC

Celldex Therapeutics, Inc.

Coherus BioSciences, Inc.

Cortice Biosciences, Inc.

Eisai

Eli Lilly and Company

EnGeneIC Ltd

ERC Belgium SA

GenSpera, Inc.

Genzyme Corporation

GW Pharmaceuticals Plc

ImmunoCellular Therapeutics, Ltd.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

AU-105



Axitinib

AXL-1717

AZD-7451

Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Hospital

Clinic

Others

If you have any special requirements, please let us know and we will offer you the report as you want.



Contents

United States Recurrent Glioblastoma Multiforme Treatment Market Report 2018

1 RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT OVERVIEW

1.1 Product Overview and Scope of Recurrent Glioblastoma Multiforme Treatment

1.2 Classification of Recurrent Glioblastoma Multiforme Treatment by Product Category

1.2.1 United States Recurrent Glioblastoma Multiforme Treatment Market Size (Sales Volume) Comparison by Type (2013-2025)

1.2.2 United States Recurrent Glioblastoma Multiforme Treatment Market Size (Sales Volume) Market Share by Type (Product Category) in 2017

1.2.3 AU-105

1.2.4 Axitinib

1.2.5 AXL-1717

1.2.6 AZD-7451

1.2.7 Others

1.3 United States Recurrent Glioblastoma Multiforme Treatment Market by Application/End Users

1.3.1 United States Recurrent Glioblastoma Multiforme Treatment Market Size (Consumption) and Market Share Comparison by Application (2013-2025)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 United States Recurrent Glioblastoma Multiforme Treatment Market by Region

1.4.1 United States Recurrent Glioblastoma Multiforme Treatment Market Size (Value) Comparison by Region (2013-2025)

1.4.2 The West Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2013-2025)

1.4.3 Southwest Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2013-2025)

1.4.4 The Middle Atlantic Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2013-2025)

1.4.5 New England Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2013-2025)

1.4.6 The South Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2013-2025)

1.4.7 The Midwest Recurrent Glioblastoma Multiforme Treatment Status and Prospect (2013-2025)



1.5 United States Market Size (Value and Volume) of Recurrent Glioblastoma Multiforme Treatment (2013-2025)

1.5.1 United States Recurrent Glioblastoma Multiforme Treatment Sales and Growth Rate (2013-2025)

1.5.2 United States Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (2013-2025)

2 UNITED STATES RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Recurrent Glioblastoma Multiforme Treatment Sales and Market Share of Key Players/Suppliers (2013-2018)

2.2 United States Recurrent Glioblastoma Multiforme Treatment Revenue and Share by Players/Suppliers (2013-2018)

2.3 United States Recurrent Glioblastoma Multiforme Treatment Average Price by Players/Suppliers (2013-2018)

2.4 United States Recurrent Glioblastoma Multiforme Treatment Market Competitive Situation and Trends

2.4.1 United States Recurrent Glioblastoma Multiforme Treatment Market Concentration Rate

2.4.2 United States Recurrent Glioblastoma Multiforme Treatment Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Recurrent Glioblastoma Multiforme Treatment Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Recurrent Glioblastoma Multiforme Treatment Sales and Market Share by Region (2013-2018)

3.2 United States Recurrent Glioblastoma Multiforme Treatment Revenue and Market Share by Region (2013-2018)

3.3 United States Recurrent Glioblastoma Multiforme Treatment Price by Region (2013-2018)

4 UNITED STATES RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)



4.1 United States Recurrent Glioblastoma Multiforme Treatment Sales and Market Share by Type (Product Category) (2013-2018)

4.2 United States Recurrent Glioblastoma Multiforme Treatment Revenue and Market Share by Type (2013-2018)

4.3 United States Recurrent Glioblastoma Multiforme Treatment Price by Type (2013-2018)

4.4 United States Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate by Type (2013-2018)

5 UNITED STATES RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Recurrent Glioblastoma Multiforme Treatment Sales and Market Share by Application (2013-2018)

5.2 United States Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate by Application (2013-2018)

5.3 Market Drivers and Opportunities

6 UNITED STATES RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Boehringer Ingelheim GmbH

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)

6.1.4 Main Business/Business Overview

6.2 Boston Biomedical, Inc.

6.2.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales,

Revenue, Price and Gross Margin (2013-2018)

6.2.4 Main Business/Business Overview



6.3 Bristol-Myers Squibb Company

6.3.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)

6.3.4 Main Business/Business Overview

6.4 Cantex Pharmaceuticals, Inc.

6.4.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)

6.4.4 Main Business/Business Overview

6.5 Cavion LLC

6.5.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales, Revenue,

Price and Gross Margin (2013-2018)

6.5.4 Main Business/Business Overview

6.6 Celldex Therapeutics, Inc.

6.6.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)

6.6.4 Main Business/Business Overview

6.7 Coherus BioSciences, Inc.

6.7.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)



6.7.4 Main Business/Business Overview

6.8 Cortice Biosciences, Inc.

6.8.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)

6.8.4 Main Business/Business Overview

6.9 Eisai

6.9.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)

6.9.4 Main Business/Business Overview

6.10 Eli Lilly and Company

6.10.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin (2013-2018)

6.10.4 Main Business/Business Overview

6.11 EnGeneIC Ltd

6.12 ERC Belgium SA

6.13 GenSpera, Inc.

6.14 Genzyme Corporation

6.15 GW Pharmaceuticals Plc

6.16 ImmunoCellular Therapeutics, Ltd.

7 RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MANUFACTURING COST ANALYSIS

7.1 Recurrent Glioblastoma Multiforme Treatment Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials



- 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
 - 7.2.1 Raw Materials
- 7.2.2 Labor Cost
- 7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Recurrent Glioblastoma Multiforme Treatment

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 8.1 Recurrent Glioblastoma Multiforme Treatment Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Recurrent Glioblastoma Multiforme Treatment Major Manufacturers in 2017
- 8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 9.1 Marketing Channel
 - 9.1.1 Direct Marketing
 - 9.1.2 Indirect Marketing
- 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
 - 9.2.1 Pricing Strategy
 - 9.2.2 Brand Strategy
 - 9.2.3 Target Client
- 9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

- 10.1 Technology Progress/Risk
- 10.1.1 Substitutes Threat
- 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

11 UNITED STATES RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Recurrent Glioblastoma Multiforme Treatment Sales Volume,



Revenue Forecast (2018-2025)

11.2 United States Recurrent Glioblastoma Multiforme Treatment Sales Volume Forecast by Type (2018-2025)

11.3 United States Recurrent Glioblastoma Multiforme Treatment Sales Volume Forecast by Application (2018-2025)

11.4 United States Recurrent Glioblastoma Multiforme Treatment Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.



List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Recurrent Glioblastoma Multiforme Treatment Figure United States Recurrent Glioblastoma Multiforme Treatment Market Size (K Pcs) by Type (2013-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume Market Share by Type (Product Category) in 2017 Figure AU-105 Product Picture Figure Axitinib Product Picture Figure AXL-1717 Product Picture Figure AZD-7451 Product Picture Figure Others Product Picture Figure United States Recurrent Glioblastoma Multiforme Treatment Market Size (K Pcs) by Application (2013-2025) Figure United States Sales Market Share of Recurrent Glioblastoma Multiforme Treatment by Application in 2017 **Figure Hospital Examples** Table Key Downstream Customer in Hospital Figure Clinic Examples Table Key Downstream Customer in Clinic **Figure Others Examples** Table Key Downstream Customer in Others Figure United States Recurrent Glioblastoma Multiforme Treatment Market Size (Million USD) by Region (2013-2025) Figure The West Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (2013-2025) Figure Southwest Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (2013-2025) Figure The Middle Atlantic Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (2013-2025) Figure New England Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (2013-2025) Figure The South of US Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (2013-2025) Figure The Midwest Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (2013-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and



Growth Rate (2013-2025)

Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (2013-2025)

Figure United States Recurrent Glioblastoma Multiforme Treatment Market Major Players Product Sales Volume (K Pcs) (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) of Key Players/Suppliers (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Sales Share by Players/Suppliers (2013-2018)

Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Sales Share by Players/Suppliers

Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Sales Share by Players/Suppliers

Figure United States Recurrent Glioblastoma Multiforme Treatment Market Major Players Product Revenue (Million USD) (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) by Players/Suppliers (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players/Suppliers (2013-2018)

Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players/Suppliers

Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players/Suppliers

Table United States Market Recurrent Glioblastoma Multiforme Treatment Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)

Figure United States Market Recurrent Glioblastoma Multiforme Treatment Average Price (USD/Pcs) of Key Players/Suppliers in 2017

Figure United States Recurrent Glioblastoma Multiforme Treatment Market Share of Top 3 Players/Suppliers

Figure United States Recurrent Glioblastoma Multiforme Treatment Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Recurrent Glioblastoma Multiforme Treatment Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Recurrent Glioblastoma Multiforme Treatment Product Category

Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Region (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Sales Share by Region (2013-2018)



Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Share by Region (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Region in 2017

Table United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Market Share by Region (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Revenue Share by Region (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Region (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Region in 2017

Table United States Recurrent Glioblastoma Multiforme Treatment Price (USD/Pcs) by Region (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Type (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Sales Share by Type (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Share by Type (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Type in 2017

Table United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Market Share by Type (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Revenue Share by Type (2013-2018)

Figure Revenue Market Share of Recurrent Glioblastoma Multiforme Treatment by Type (2013-2018)

Figure Revenue Market Share of Recurrent Glioblastoma Multiforme Treatment by Type in 2017

Table United States Recurrent Glioblastoma Multiforme Treatment Price (USD/Pcs) by Types (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate by Type (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Application (2013-2018)

Table United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Application (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share



by Application (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Application in 2017

Table United States Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate by Application (2013-2018)

Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate by Application (2013-2018)

Table Boehringer Ingelheim GmbH Basic Information List

Table Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)

Figure Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018)

Table Boston Biomedical, Inc. Basic Information List

Table Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K

Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)

Figure Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018)

Table Bristol-Myers Squibb Company Basic Information List

Table Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)

Figure Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018)

Table Cantex Pharmaceuticals, Inc. Basic Information List

Table Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)



Figure Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment

Revenue Market Share in United States (2013-2018)

Table Cavion LLC Basic Information List

Table Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs),

Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)

Figure Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018)

Table Celldex Therapeutics, Inc. Basic Information List

Table Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)

Figure Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018)

Table Coherus BioSciences, Inc. Basic Information List

Table Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)

Figure Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018)

Table Cortice Biosciences, Inc. Basic Information List

Table Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

Figure Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)

Figure Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018)

Figure Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue



Market Share in United States (2013-2018) Table Eisai Basic Information List Table Eisai Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Eisai Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013 - 2018)Figure Eisai Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018) Figure Eisai Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018) Table Eli Lilly and Company Basic Information List Table Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018) Figure Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales Market Share in United States (2013-2018) Figure Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue Market Share in United States (2013-2018) Table EnGeneIC Ltd Basic Information List Table ERC Belgium SA Basic Information List Table GenSpera, Inc. Basic Information List Table Genzyme Corporation Basic Information List Table GW Pharmaceuticals Plc Basic Information List Table ImmunoCellular Therapeutics, Ltd. Basic Information List Table Production Base and Market Concentration Rate of Raw Material Figure Price Trend of Key Raw Materials Table Key Suppliers of Raw Materials Figure Manufacturing Cost Structure of Recurrent Glioblastoma Multiforme Treatment Figure Manufacturing Process Analysis of Recurrent Glioblastoma Multiforme Treatment Figure Recurrent Glioblastoma Multiforme Treatment Industrial Chain Analysis Table Raw Materials Sources of Recurrent Glioblastoma Multiforme Treatment Major Players/Suppliers in 2017 Table Major Buyers of Recurrent Glioblastoma Multiforme Treatment Table Distributors/Traders List Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)

Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million



USD) and Growth Rate Forecast (2018-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Price (USD/Pcs) Trend Forecast (2018-2025) Table United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) Forecast by Type (2018-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) Forecast by Type (2018-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) Forecast by Type in 2025 Table United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) Forecast by Application (2018-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) Forecast by Application (2018-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) Forecast by Application in 2025 Table United States Recurrent Glioblastoma Multiforme Treatment Sales Volume (K Pcs) Forecast by Region (2018-2025) Table United States Recurrent Glioblastoma Multiforme Treatment Sales Volume Share Forecast by Region (2018-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume Share Forecast by Region (2018-2025) Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Volume Share Forecast by Region in 2025 Table Research Programs/Design for This Report Figure Bottom-up and Top-down Approaches for This Report Figure Data Triangulation Table Key Data Information from Secondary Sources Table Key Data Information from Primary Sources



I would like to order

Product name: United States Recurrent Glioblastoma Multiforme Treatment Market Report 2018 Product link: <u>https://marketpublishers.com/r/U31118D96BFEN.html</u>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/U31118D96BFEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970